Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EJ8K
|
|||
| Former ID |
DIB003048
|
|||
| Drug Name |
GSK-2392102A
|
|||
| Synonyms |
GSK-2392019A; GSK-2392103A; GSK-2392105A; GSK-2392106A; Staphylococcus aureus vaccine (4 component), GlaxoSmithKline
Click to Show/Hide
|
|||
| Indication | Staphylococcus infection [ICD-11: 1B5Y; ICD-10: A49.0; ICD-9: 001-139] | Phase 1 | [1] | |
| Company |
Glaxosmithkline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01160172) A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.